Biotech Movers: Seattle Genetics, FibroGen, Sangamo

Biotech Movers: Seattle Genetics, FibroGen, Sangamo


Shares of Seattle Genetics Inc. were down 7.8% to $56.95 in premarket trading on Monday, June 26. Seattle Genetics and Takeda Pharmaceutical Co. Ltd. on Monday said a Phase 3 study of adcetris as part of a frontline combination chemotherapy in patients with previously untreated advanced classical Hodgkin lymphoma met its primary endpoint.



from Biotech News